These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 2529993

  • 1. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas].
    Chen YF.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun; 11(3):229-31. PubMed ID: 2529993
    [Abstract] [Full Text] [Related]

  • 2. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
    Chen YF, Mai CR, Tie ZJ, Feng ZT, Zhang J, Lu XH, Lu GJ, Xue YH, Pan GZ.
    Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154
    [Abstract] [Full Text] [Related]

  • 3. CA 19-9 in serum and pancreatic juice: its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis.
    Malesci A, Evangelista A, Mariani A, Bersani M, Bonato C, Basilico M, Montorsi M, Beretta E.
    Int J Pancreatol; 1988 May; 3 Suppl 1():S119-23. PubMed ID: 3209865
    [Abstract] [Full Text] [Related]

  • 4. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K, Tasaki N, Miyagawa H, Yoshikawa T, Kondo M.
    Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
    [Abstract] [Full Text] [Related]

  • 5. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
    Hyöty M, Hyöty H, Aaran RK, Airo I, Nordback I.
    Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
    [Abstract] [Full Text] [Related]

  • 6. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
    Czakó L, Takács T, Babarczy E, Dux L, Lonovics J.
    Orv Hetil; 1997 Nov 23; 138(47):2981-5. PubMed ID: 9432648
    [Abstract] [Full Text] [Related]

  • 7. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT, Tao HQ, Zou SC.
    Hepatobiliary Pancreat Dis Int; 2004 Aug 23; 3(3):464-8. PubMed ID: 15313690
    [Abstract] [Full Text] [Related]

  • 8. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
    Safi F, Roscher R, Beger HG.
    Hepatogastroenterology; 1989 Dec 23; 36(6):419-23. PubMed ID: 2613165
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
    Satake K, Chung YS, Umeyama K, Takeuchi T, Kim YS.
    Gan To Kagaku Ryoho; 1989 Apr 23; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
    [Abstract] [Full Text] [Related]

  • 11. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003 Apr 23; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tumour markers in pancreatic cancer.
    Haglund C, Kuusela P, Roberts PJ.
    Ann Chir Gynaecol; 1989 Apr 23; 78(1):41-53. PubMed ID: 2667448
    [Abstract] [Full Text] [Related]

  • 14. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Haglund C.
    Anticancer Res; 2002 Apr 23; 22(4):2311-6. PubMed ID: 12174919
    [Abstract] [Full Text] [Related]

  • 15. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
    Schmiegel WH, Eberl W, Kreiker C, Kalthoff H, Bützow GH, Jessen K, Klapdor R, Soehendra N, Wargenau M, Classen M.
    Hepatogastroenterology; 1985 Jun 23; 32(3):141-5. PubMed ID: 2410346
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ.
    Chin J Dig Dis; 2006 Jun 23; 7(3):170-4. PubMed ID: 16808798
    [Abstract] [Full Text] [Related]

  • 17. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma.
    Safi F, Roscher R, Beger HG.
    Bull Cancer; 1990 Jun 23; 77(1):83-91. PubMed ID: 2180502
    [Abstract] [Full Text] [Related]

  • 18. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
    Piantino P, Andriulli A, Gindro T, Pecchio F, Masoero G, Cavallini G, Naccarato R, Dobrilla G.
    Am J Gastroenterol; 1986 Jun 23; 81(6):436-9. PubMed ID: 3458359
    [Abstract] [Full Text] [Related]

  • 19. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
    Wu JT.
    Ann Clin Lab Sci; 1989 Jun 23; 19(1):17-26. PubMed ID: 2916833
    [Abstract] [Full Text] [Related]

  • 20. [Tumor markers in the diagnosis of tumors in the subhepatic area].
    Dufek V, Petrtýl J, Klener P, Chmel J.
    Vnitr Lek; 1994 Jun 23; 40(6):350-3. PubMed ID: 8073643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.